How much funding has Nuvalent raised?

Nuvalent has raised $185.0M in total funding, most recently a Series B round.

Who are Nuvalent's investors?

Nuvalent's investors include Deerfield Management, GSK, Wellington Management, Bain Capital Life Sciences.

Where is Nuvalent headquartered?

Nuvalent is headquartered in Cambridge, Massachusetts, United States.

What industry is Nuvalent in?

Nuvalent operates in Biotech, Healthcare.

Nuvalent

Acquired

Precisely targeted therapies for patients with cancer

Public · Cambridge, United States · Founded 2017 · $185.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2017
Business Model: B2B
Website: nuvalent.com

Total Funding: $185.0M
Last Round: $135.0M Series BMay 2021
Rounds: 3
Type: Public

About

Nuvalent is a clinical-stage biopharmaceutical company advancing precisely targeted therapies for cancer using structure-based drug discovery and small molecule chemistry. Its pipeline focuses on kinase inhibitors zidesamtinib (NVL-520) for ROS1-positive NSCLC and neladalkib (NVL-655) for ALK-positive NSCLC, with NVL-330 targeting HER2-altered NSCLC. GSK entered an agreement to acquire Nuvalent in June 2026.

Summary

Nuvalent is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $185.0M in total across 3 rounds, most recently a $135.0M Series B round in May 2021. Investors include Deerfield Management, GSK and Wellington Management.

LinkedIn X (Twitter)